PACS Group (NYSE:PACS – Get Free Report) and Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for PACS Group and Intelligent Bio Solutions, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PACS Group | 0 | 1 | 4 | 1 | 3.00 |
| Intelligent Bio Solutions | 1 | 0 | 0 | 0 | 1.00 |
PACS Group currently has a consensus target price of $44.40, suggesting a potential upside of 30.13%. Given PACS Group’s stronger consensus rating and higher possible upside, equities analysts plainly believe PACS Group is more favorable than Intelligent Bio Solutions.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PACS Group | $5.29 billion | 1.01 | $191.54 million | $1.23 | 27.74 |
| Intelligent Bio Solutions | $3.05 million | 2.15 | -$10.57 million | ($14.82) | -0.28 |
PACS Group has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
PACS Group has a beta of -0.64, meaning that its stock price is 164% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.58, meaning that its stock price is 358% more volatile than the S&P 500.
Insider & Institutional Ownership
33.0% of Intelligent Bio Solutions shares are held by institutional investors. 70.4% of PACS Group shares are held by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares PACS Group and Intelligent Bio Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PACS Group | 3.62% | 22.55% | 3.45% |
| Intelligent Bio Solutions | -315.33% | -200.68% | -97.31% |
Summary
PACS Group beats Intelligent Bio Solutions on 12 of the 15 factors compared between the two stocks.
About PACS Group
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for PACS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PACS Group and related companies with MarketBeat.com's FREE daily email newsletter.
